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Abstract
Background: This phase I study was designed to determine the bioavailability and bioequivalence
of 400 mg Eudorlin® extra* (Ibuprofen) in comparison to two reference formulations (400 mg
Nurofen® forte and 400 mg Migränin® after single dose administration under fasting conditions in
healthy subjects. Therefore the design of a randomized, open label, multiple sequence cross-over
study with a wash-out period of 7–10 days was used.
Results:  AUC0-t(last) and AUC0-∞ (90%CI) were within the 80 to 125% interval required for
bioequivalence as stipulated in the current regulations of the EMEA. Cmax (90%CI) was within the
EMEA acceptance range of 75 to 133%. Detailed analyses showed that Cmax of Eudorlin® extra was
higher than that of Nurofen® forte (36.62 vs. 32.92 μg/ml; p = 0.0014) and that of Migränin® (35.94
vs. 30.87 μg/ml; p < 0.0001). The time to maximum plasma concentration (tmax) was shorter with
Eudorlin® extra than with Nurofen forte (1.14 vs. 1.82 h; p < 0.0001) and Migränin (1.13 vs. 1.78 h;
p = 0.0031). Only 1 patient experienced an adverse with possible relation to the study drug taking
Migränin®.
Conclusion:  It is concluded that Eudorlin®  extra is bioequivalent to the two reference
preparations Nurofen® forte and Migränin® for both, the extent and the rate of absorption, after
single dose administration in healthy volunteers according to the guidance of the EMEA. Within this
frame, peak plasma concentrations are however reached earlier and peaks are higher compared to
the reference products.
* Eudorlin® extra may have different brand names in different countries
Background
Ibuprofen was developed during the 1950s and 1960s as
a 'super aspirin' for the treatment of rheumatoid arthritis
which was as effective as current alternatives but safer.
First synthesised in December 1961 ibuprofen was found
to have a short elimination half-life and exceptional gas-
trointestinal tolerability [1]. Ibuprofen is mostly used
today in the management of mild to moderate pain and
inflammation in conditions such as dysmenorrhoea,
headache including migraine, postoperative pain, dental
pain, musculoskeletal and joint disorders such as ankylos-
ing spondylitis, osteoarthritis, and rheumatoid arthritis. It
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is also used to reduce fever. The usual oral dose in adults
is 400 to 800 mg daily for analgesia and up to 1600 to
2400 mg for its anti-inflammatory action [2].
Ibuprofen is absorbed from the gastro-intestinal tract and
peak plasma concentrations are reached within about 1 to
2 hours after ingestion. Bioavailability is ≥ 80%. 99% of
ibuprofen is bound to plasma proteins, 90% is trans-
formed to 2 inactive metabolites and it has a plasma half-
life of about 2 ± 0.5 hours. It is rapidly excreted in the
urine mainly as metabolites and their conjugates. About
1% is excreted in urine as unchanged ibuprofen [2].
The European Agency for the Evaluation of Medicinal
Products (EMEA) requires generic products that enter the
marketplace to show bioequivalence to assess the possi-
bility of alternative use between the reference product and
an essentially similar medicinal product [3]. This is done
assuming that in the same subject an essentially similar
plasma concentration time course will result in essentially
similar concentrations at the site of action and thus in an
essentially similar effect. Medicinal products authorized
and marketed on the basis of a full dossier i.e. including
chemical, biological, pharmaceutical, pharmacological-
toxicological and clinical data are used as the reference
product.
The present study was designed to investigate the bioavail-
ability and the bioequivalence of 400 mg Eudorlin® extra
in comparison to two reference products – Migränin® and
Nurofen® forte after single oral administration (fasting
conditions) in healthy subjects following the EMEA guid-
ance [3]. Two reference products were used since different
reference formulations were required in different coun-
tries. For this purpose the rate and extent of absorption of
ibuprofen under fasting conditions after administration
of one tablet of the test product (Eudorlin® extra) and one
tablet of each of the reference products were compared in
a three sequence cross-over design.
Results
Demography and baseline characteristics
Between February 3rd and March 8th 2007 86 subjects were
screened for eligibility of whom 60 were enrolled, rand-
omized and available for pharmacokinetic and safety
analyses. 41 of these were male, 19 female. There were
three protocol violations (Per-protocol population n =
57). For the first patient the labelling of two blood sam-
ples was missing, the other two patients missed at least
one visit with missing information for that particular time
point. Table 1 displays the patient characteristics of the
pharmacokinetic population by treatment sequence. A
refers to reference product Nurofen® forte, B to reference
product Migränin® and E to test product Eudorlin® extra.
Dissolution testing
Results of dissolution testing are displayed in Figure 1.
Testing was performed for the three products using a total
of 504 samples for different time points. All samples
resulted in values between 0 and a maximum of 104%.
Dissolution was particularly fast with Eudorlin®  extra
resulting in 99% released ibuprofen within 5 minutes.
Table 1: Demographic data of subjects
Parameter Sequence N Mean SD Median Range
Age (years) BE 20 23.9 3.65 23.5 20; 35
EA 20 25.1 5.01 24.0 20; 39
A E B 2 0 2 7 . 86 . 5 72 6 . 5 2 0 ;  4 5
Weight (kg) BE 20 68.3 10.74 69.5 50; 90
EA 20 67.7 9.54 68.5 49; 82
AEB 20 67.9 10.48 68.0 52; 87
BMI (kg/m2)  * B E 2 0 2 2 . 82 . 4 02 3 . 0 1 9 ;  2 7
EA 20 22.9 2.29 23.0 19; 27
A E B 2 0 2 2 . 22 . 6 72 2 . 0 1 9 ;  2 7
Sequence N N ()%  ( )N  ( )%  ( )
Female gender (%) BE 20 7 35.0 13 65.0
EA 20 6 30.0 14 70.0
AEB 20 6 30.0 14 70.0
Demography and other baseline characteristics by treatment sequence (Pharmacokinetic population; N = 60). "A" refers to Nurofen® forte, "B" 
refers to Migränin® and "E" refers to Eudorlin® extra. * calculated from measured height (m) and weight (kg).BMC Pharmacology 2008, 8:18 http://www.biomedcentral.com/1471-2210/8/18
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About the same dissolution was observed after 45 minutes
with Nurofen®  forte (99%) and 30 minutes using
Migränin® (100%).
Pharmacokinetic
Table 2 displays the pharmacokinetic parameters of the
pharmacokinetic (PK) population (n = 60). Table 3 illus-
trates the statistical analysis. AUC0-t(last) and AUC0-∞ was
similar for the comparison of Eudorlin® extra with Nuro-
fen® forte and Eudorlin® extra with Migränin®. All esti-
mates of the ratios for the parameters AUC0-t(last) and
AUC0-∞ were near to 1.00 and the 90%-confidence inter-
vals for all comparisons were within the acceptance range
of 0.80 – 1.25.
The mean Cmax of ibuprofen differed after Eudorlin® extra
compared to Nurofen® forte (36.62 vs. 32.92 μg/ml; p =
0.0014) and after Eudorlin® extra compared to Migränin®
(35.94 vs. 30.87 μg/ml; p < 0.0001). The 90%-confidence
intervals for both comparisons were however within the
widened acceptance range of 0.75 – 1.33 (pre-defined),
but also within the standard acceptance range of 0.80 –
1.25.
The tmax varied for Eudorlin® extra between 0.25 to 3.50
hours and after treatment with Nurofen®  forte or
Migränin® between 0.50 and 5.00 hours (Table 2 displays
the mean values ± standard deviation). The difference in
tmax of Eudorlin® extra and Nurofen® was statistically sig-
nificant (1.14 vs. 1.82 h; p < 0.0001) as was the difference
between Eudorlin® extra and Migränin® (1.13 vs. 1.78; p =
0.0031).
As an additional variable the elimination half life t1/2 was
calculated. The mean elimination half life t1/2 values were
similar for all treatments with 2.52 hours after Nurofen®
Results of dissolution testing Figure 1
Results of dissolution testing. Dissolution testing of 400 mg tablets Eudorlin® Extra (Test formulation, in red) versus 400 
mg Nurofen® Forte (Reference formulation 1, black) and 400 mg Migränin® (Reference formulation 2, broken black).
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forte, 2.50 hours after Migränin® and slightly higher after
Eudorlin® e x t r a  w i t h  2 . 5 5  o r  2 . 6 6  h o u r s  c o m p a r e d  t o
Migränin® or Nurofen® forte respectively.
The graphic geometric mean time curves for plasma con-
centration for Eudorlin® extra compared to the reference
products – Nurofen® forte and Migränin® were similar with
a slightly higher and earlier geometric mean maximum for
Eudorlin® extra (see Figures 2 and 3).
Safety
14 subjects of the safety population (N = 60) reported a
total of 20 adverse events during the study, 6 of these sub-
jects after treatment with Eudorlin® extra, 6 after Nurofen®
forte and 4 after Migränin®. The only adverse event with a
possible relation to the study drug was headache reported
by 1 subject after intake of Migränin®. 19 were unrelated
and 2 unlikely drug related.
Discussion
The results of this study demonstrate that a single dose of
Eudorlin® extra results in similar total systemic exposure
Table 2: Pharmacokinetic parameters
Parameter analyzed Sequence Treatment Mean SD CV (%) Geometric mean
AUC0-t(last) (μg/ml*h) AE/EA Nurofen® 117.00 31.94 27.3 113.4
Eudorlin® 119.79 29.04 24.2 116.6
EB/BE Migränin® 115.21 21.83 19.0 113.1
Eudorlin® 115.84 22.73 19.6 113.7
AUC0-∞ (μg/ml*h) AE/EA Nurofen® 117.38 32.01 27.3 113.8
Eudorlin® 120.15 29.07 24.2 117.0
EB/BE Migränin® 115.57 21.84 18.9 113.5
Eudorlin® 116.22 22.73 19.6 114.1
Cmax (μg/ml) AE/EA Nurofen® 32.92 8.29 25.2 31.83
Eudorlin® 36.62 6.16 16.8 36.11
EB/BE Migränin® 30.87 6.31 20.4 30.25
Eudorlin® 35.94 6.30 17.5 35.41
t1/2 (h) AE/EA Nurofen® 2.52 0.44 17.6 2.495
Eudorlin® 2.55 0.42 16.6 2.522
EB/BE Migränin® 2.50 0.33 13.1 2.478
Eudorlin® 2.66 0.79 29.8 2.583
Mean SD CV Median
tmax (h) AE/EA Nurofen® 1.82 1.05 57.9 1.50
Eudorlin® 1.14 0.67 59.1 1.00
EB/BE Migränin® 1.78 0.97 54.5 1.75
Eudorlin® 1.13 0.80 71.1 0.75
Pharmacokinetic data by treatment pair and treatment (Pharmacokinetic population; N = 60). "A" refers to Nurofen® forte, "B" refers to Migränin® 
and "E" refers to Eudorlin® extra. SD: standard deviation, CV: coefficient of variation.
Table 3: Statistical analysis for AUC0-t(last), AUC0-∞ and Cmax
Parameter Ratio Estimate 90%CI
AUC0-t(last) E/A 1.0241 0.9959; 1.0531
E/B 1.0058 0.9700; 1.0430
AUC0-∞ E/A 1.0240 0.9958; 1.0529
E/B 1.0060 0.9704; 1.0430
Cmax E/A 1.1084 1.0542; 1.1852
E/B 1.1732 1.1058; 1.2447
Parameter Difference Estimate 90%CI
tmax E – A -0.6250 -0.8750; -0.3750
E – B -0.6875 -1.000; -0.3750
Statistical analysis by treatment pair (parametric analysis, 
pharmacokinetic population; N = 60). "A" refers to Nurofen® forte, 
"B" refers to Migränin® and "E" refers to Eudorlin® extra. CI: 
confidence interval.BMC Pharmacology 2008, 8:18 http://www.biomedcentral.com/1471-2210/8/18
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(as measured by AUC) compared to Nurofen® forte and
after Migränin® throughout a 24 h period. However, the
peak plasma concentration (Cmax) was higher and the
time to peak plasma concentration (tmax) shorter in com-
parison to the two reference formulations suggesting a
more rapid absorption of the test formulation (for illus-
tration see Figures 2 and 3). These results are consistent
with the results of the dissolution testing which suggested
a faster release of ibuprofen from the test formulation. All
measures are however within the acceptance range of the
EMEA bioequivalence guidance [3]. This asks to demon-
strate that the 90% confidence interval of AUC0-t(last),
AUC0-∞ and Cmax lie within an acceptance range of 80 –
125% while tmax should lie within a clinically determined
range but is not further specified.
Acceptance range peak plasma concentration (Cmax)
Ibuprofen has shown to have a low acute and chronic tox-
icity in a number of clinical studies and registries [2], in
particular using the low dose tested. An evaluation of
reported side effects after single doses in 15 double-blind
randomized trials [4] demonstrated that these were
equally distributed across all doses tested. Out of 707
patients 13 (1.8%) reported side effects, 4 of which
reported GI-related adverse events. The study protocol
considered bioequivalence to be acceptable when the
90% confidence interval was between 75 – 133% based
on a large body of bioequivalence studies comparing
generic formulations of 400 mg ibuprofen with the refer-
ence formulation (Brufen 400 mg in most cases) [5].
Additional file 1 displays the results from these studies,
illustrating that the Cmax of generic formulations varies
Plasma concentration time curve Eudorlin® vs. Nurofen® Figure 2
Plasma concentration time curve Eudorlin® vs. Nurofen®. Geometric mean time curve for plasma concentration of 
ibuprofen; cross-over Eudorlin® extra – Nurofen® forte (Pharmacokinetic population; N = 60).
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substantially from 28.7 (Motrin® to 43.3 (Ibuprofen 400®
Stada).
Cmax values reported for the present study proved to be
within the range of the wide (75 – 133%) but as well
within the narrow confidence interval (80 – 125%) and
are compatible with the other studies conducted [5],
including the data of a recently published report by Bien-
ert et al. [6].
Rate and extent of absorption (Cmax and tmax)
A quick release of ibuprofen in the gastrointestinal tract
following oral administration is desirable [7] to achieve
rapid pain relief and to avoid overdosing due to multiple
ingestions based on a prolonged onset of action. As serum
concentrations of ibuprofen and its analgesic effect are
highly correlated, rapid ibuprofen absorption is the sole
prerequisite for the quick onset of its action. Because its
membrane permeability approaches up to 100% dissolu-
tion of the tablet becomes the rate limiting step for
absorption [8]. A more rapid pain relief could translate in
higher patient satisfaction and less danger of repeated ibu-
profen intake due to slow onset of action.
It has been shown in the present study that Eudorlin® extra
tablets are rapidly dissolved in vitro resulting in 99% dis-
solution after only 5 minutes. In comparison it took 30
and 45 min respectively for the two reference formula-
tions to achieve a similar degree of dissolution. This
observation is compatible with the faster (tmax) and higher
peak plasma concentration (Cmax) observed in the present
cross-over study in healthy volunteers. The values
obtained did on the other hand not trespass the prede-
Plasma concentration time curve Eudorlin® vs. Migränin® Figure 3
Plasma concentration time curve Eudorlin® vs. Migränin®. Geometric mean time curve for plasma concentration of 
ibuprofen; cross-over Eudorlin® extra – Migränin® (Pharmacokinetic population; N = 60).
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fined acceptance range for Cmax as outlines above, thus not
questioning the assumption of bioequivalence.
Conclusion
Statistical analyses of primary parameters provided evi-
dence for the therapeutic equivalence of the three ibupro-
fen formulations: the 90%-confidence intervals for the
comparison Eudorlin® extra/Nurofen® forte and Eudorlin®
extra/Migränin® were within the predefined acceptance
range of 0.80 – 1.25 for both, AUC0-t(last) and AUC0-∞ and
within the acceptance range of 0.75 – 1.33 for the param-
eter Cmax. Peak plasma concentration was however higher
and the time to peak plasma concentration shorter, com-
patible with a more rapid pain relief with Eudorlin® extra.
All three formulations were well tolerated. The only
adverse event with a possible relation to the study drug
was reported by one subject after Migränin® exposure.
Methods
Study design and inclusion criteria
This phase I study (study code 398B6) was a single-dose,
randomized, open label, three-treatment, three-period,
three-sequence cross-over with a wash-out period of 7–
10 days. Patients were eligible for inclusion if they were
male or female of Caucasian origin, between 18 and 55
years of age, a body mass index (BMI) of between 19 and
28 kg/m2 and had provided written informed consent
prior to study participation. Women of childbearing age
had to be negative on a pregnancy test and had to agree
to be either sexually inactive for 30 days prior to study
participation or use an appropriate method of contra-
ception.
Test product
Film coated tablets of ibuprofen (Eudorlin® extra for oral
administration, batch number 62020, expiry date 05/
2009) were tested against two reference formulations of
ibuprofen: Nurofen® forte (Ibuprofen 400 mg coated tab-
lets, batch number 13J, expiry date 06/2009 and
Migränin®  (Ibuprofen 400 mg coated tablets, batch
number 12J, expiry date 06/2008). Dissolution testing
was performed at pharm-analyt Labor GmbH, Baden,
Austria between February 23rd and March 15th 2007 using
a HPLC-UV technique.
Allocation of subjects to the appropriate sequence groups during the study Figure 4
Allocation of subjects to the appropriate sequence groups during the study. S: Sequence groups; A: subjects receiv-
ing drug A (Nurofen® forte), B: subjects receiving drug B (Migränin®, E: subjects receiving Eudorlin® extra.
S1 B B
S2 E E E
S3 A A
Period 1 Wash-out 1 Period 2 Wash-out 2 Period 3BMC Pharmacology 2008, 8:18 http://www.biomedcentral.com/1471-2210/8/18
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Treatment protocol
A three sequence cross-over design, allowed for the com-
parison of different subject sequences: 1) Subjects who
received Nurofen® forte (A) during periods 1 and 2 com-
pared to subjects who received Eudorlin® extra (E) during
these periods (1 and 2) (sequence AE/EA); 2) Subjects
who received Migränin® (B) during period 2 and 3 com-
pared to subjects who received Eudorlin® extra (E) during
these periods (2 and 3) (sequence EB/BE). The study con-
sisted of three treatment phases separated by wash-out
periods of 7 to 10 days (Figure 4). At least 12 h before each
treatment period the subjects were admitted to the site.
After an overnight fasting of at least 10 h subjects were
administered 400 mg ibuprofen in sitting position
between 8 and 9 a.m. (time point 0). Blood samples (6 ml
each) were collected from all subjects 12 min prior to dos-
ing and at 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, 2.5, 3.0,
3.5, 4.0, 5.0, 6.0, 8.0, 10.0, 12.0, 16.0 and 24.0 hours after
drug administration. Patients were observed for a total of
36 h (12 h prior until 24 h after drug administration). The
blood samples were collected in heparinised tubes and
cooled immediately in an ice bath and centrifuged at 3500
r.p.m. under refrigeration to obtain plasma. Immediately
after centrifugation the plasma was homogenized, the
tubes capped and stored frozen at -20°C.
Clinical examination
Personal data, medical history, physical examinations
(height, weight, 12-lead ECG), vital signs (blood pressure,
heart rate, temperature) and laboratory tests were
obtained during the screening phase. During each treat-
ment period, vital signs and adverse events were recorded.
Clinical safety parameters included a general medical
examination, heart rate and blood pressure (sitting posi-
tion) and the documentation of adverse events. Clinical
laboratory safety was assessed with clinical chemistry,
haematology, urinalysis, pregnancy test, HIV, HbsAg and
HCV screening, urine drug screening and an alcohol
breath test. Within a 7 day time frame after last blood
sampling an ECG, clinical laboratory parameters and
physical examination were repeated.
Analytical method and chromatographic system
Determination was conducted considering GLP-guide-
lines [9]. Procedure of validation and acceptance criteria
were based on the rules and guidelines of the FDA [10]
and of the ICH Consensus Guidelines. Pre-study valida-
tion of the method was performed by documentation of
specificity, linearity, limit of quantification, precision and
accuracy. Furthermore recovery rate and stability of ibu-
profen in plasma samples were investigated. For in-study
validation each run contained samples for the calculation
of standard curves; quality control samples and the sam-
ples of the subjects. The run was accepted, if no more than
two of six quality control samples were outside ± 15%
from the nominal value.
Determination of ibuprofen was performed using HPLC
method with fluorescence detection [11]. A Merck-Hitachi
L-7485 was used for detection of ibuprofen (excitation
225 nm, emission 290 nm). Chromatographic separation
was carries out using a Luna 5 μC18(2) 100A, 50 × 2.0
mm (Phenomenex, USA). The mobile phase was 35%
0.02 molar phosphoric acid: 65% MeOH (v/v). The flow
rate was 1.0 ml/min.
A sample volume of 250 μl was analyzed and a volume of
10  μl injected onto the chromatographic column. The
method was validated between 0.200 and 75.0 μg/ml. In
this study the retention time was 1.5 min. The blank sam-
ple showed no peaks in the retention time window of
interest.
The assay showed an acceptable linearity over a concentra-
tion range from 0.200 to 75.0 μg/ml (r ≥ 0.99, n = 8). The
limit of detection defined as baseline noise was 0.206 μg/
l. Specificity: There were no interfering peaks for the endog-
enous compound for the blank plasma at the retention
time of ibuprofen (1.5 min.). The inter-batch precision was
between 9.96% for 0.500 μg/ml and 6.35% for 63.8 μg/
ml. The within-batch precision was between 1.56% for
0.206  μg/ml and 5.83% for 75.0 μg/ml. The accuracy
(bias) for ibuprofen was expressed as a percent deviation
of observed plasma concentration from theoretical con-
centration (0.5, 5.51 and 63.8 μg/ml). The accuracy
ranged from 1.3% (0.500 μg/ml) to 4.5% (5.51 μg/ml).
For the determination of recovery peak areas determined
following analysis of calibration standards with concen-
trations of 0.5, 5.51 and 63.8 μg/ml were compared with
data obtained by direct injection of aqueous solutions of
these concentrations. The mean recovery of ibuprofen
from spiked plasma samples was on average 92.2%.
Statistics
Sample size was based on a intra-individual CV of 26%
based on a previous bioavailability study of Eudorlin®
extra (Clinical trial report BCBe/02/Ibu-BV-001) and data
from Blume and Mutschler [5]. For a total of 36 subjects
(2 × 18) the power to detect bioequivalence was 96%
assuming a true ratio of 0.95, and 98% assuming a true
ratio of 1.05 (calculations based on equivalence limits of
0.75 and 1.33). As bioequivalence had to be shown with
2 reference products sample size was adjusted to 3 × 18
(54) subjects. Therefore 60 patients were included to
allow a drop-out of 10% (6 subjects).
The statistical analyses were performed by using SAS 8.2
[12]. The primary pharmacokinetic parameters after loga-Publish with BioMed Central    and   every 
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rithmic transformation (multiplicative model) were sub-
jected to an analysis of variance (ANOVA) with the factors
SEQUENCE, SUBJECT nested within SEQUENCE,
PERIOD and FORM (drug formulation) using a general
linear model procedure. For assessment of bioequivalence
90%-confidence intervals for the formulation ratio in the
parameters AUCt (calculated using the trapezoidal rule),
AUC∞ (calculated as sum of AUCt and the extrapolated
area using the last measured concentration [C(last)] and the
elimination half life by taking the formula: [C(last) × t1/2/
ln2]), and Cmax (directly obtained from measured values)
of ibuprofen were calculated using the ln-transformed
data. Bioequivalence was accepted if the calculated 90%-
confidence intervals were within 0.80 – 1.25 for AUCt and
within 0.75 – 1.33 for Cmax. Possible side effects of the
study medication and any adverse events were listed. Time
of maximum plasma concentration (tmax) was directly
obtained from measured values and compared using the
two samples Wilcoxon test. Elimination half life (t1/2) was
calculated from concentrations of the elimination phase
using semi-log transformed data and linear regression was
documented individually.
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